Menopause Treatment: What Actually Works for Hot Flashes, Sleep, and Long-Term Health

Short Answer

Menopause treatment works best when it is layered around your body, your risks, and your actual symptoms — not built around one "miracle" pill or supplement. The base layer is still the unglamorous one: sleep protection, regular movement, enough protein and fiber, heart-healthy food, stress downshifting, and strength or weight-bearing exercise. These steps may not switch off a hot flash in the moment, but they help your nervous system, blood sugar, blood pressure, muscles, and bones adapt to the lower-estrogen state after menopause. After menopause, lower estrogen is linked with higher risk of osteoporosis and heart disease, so treatment should not only ask, "How do we stop the sweating?" but also, "How do we protect your next 10, 20, 30 years?" (Cleveland Clinic: Menopause treatment)

For hot flashes and night sweats, menopausal hormone therapy — also called MHT or HRT — remains the most effective medical option for many people who are good candidates. The "good candidate" part matters. Current evidence frames the benefit-risk balance as more favorable for many symptomatic women who are younger than 60 or within 10 years of menopause onset, and less favorable when therapy starts later, because absolute risks such as coronary heart disease, stroke, blood clots, and dementia rise with age and timing. That is why MHT is not a wellness shortcut; it is a shared medical decision based on your uterus status, age, time since your final period, migraine and clot history, breast cancer risk, cardiovascular risk, symptom severity, and preferences. (2022 NAMS Hormone Therapy Position Statement, PubMed)

If hormones are not a fit — or you simply do not want them — there are evidence-based non-hormonal options. These include certain SSRI/SNRI antidepressant classes, gabapentin, oxybutynin, and fezolinetant, a newer non-hormonal neurokinin-3 receptor antagonist approved by the FDA for moderate-to-severe menopause-related hot flashes. These medicines work through different pathways: mood and temperature signaling, nerve excitability, sweat/heat-response circuits, or the brain's thermoregulation center. They are not interchangeable, and some need specific safety checks, so the choice should be matched to your sleep, mood, blood pressure, liver health, medications, and side-effect tolerance. (2023 NAMS Nonhormone Therapy Position Statement, PubMed)

Vaginal dryness, painful sex, recurrent irritation, and some urinary symptoms are a different problem from whole-body hot flashes. They often come from thinner, drier, more fragile vaginal and urinary tissues after estrogen drops. For these symptoms, local vaginal treatment — moisturizers and lubricants first for some people, then low-dose vaginal estrogen or other local therapies when needed — can be considered separately from systemic hormone therapy. In other words, needing help with vaginal or urinary symptoms does not automatically mean you need full-body hormones. (National Institute on Aging: Sex and menopause)

So the practical answer is: start with the body-wide foundations, treat the most disruptive symptom first, and choose the smallest effective medical layer that fits your risk profile. The best menopause relief is usually not "natural" versus "medical." It is the plan that helps you sleep, function, cool down, protect bone and heart health, and keep checking in as your symptoms change.

Start With the Foundation: Lifestyle That Actually Moves the Needle

Before — or alongside — medication, lifestyle is the base layer. Not because it is "gentler" or more virtuous, but because menopause symptoms do not happen in a vacuum. Shifts in estrogen affect the brain's temperature regulation, sleep, mood, body composition, and long-term cardiometabolic and bone risk. That means the same daily inputs that may soften hot flashes or night sweats can also protect your future heart, bones, weight, and glucose metabolism. A 2025 review describes lifestyle medicine as a structured non-drug framework for menopause care, with interventions linked to better sleep, mental well-being, weight regulation, and lower cardiometabolic and osteoporosis risk (*Climacteric*, 2025, PMID 40937901):

"Lifestyle medicine — encompassing healthy eating, physical activity, mental well-being, avoidance of risky substances, restorative sleep and healthy relationships — offers a promising non-pharmacological strategy to optimize health during this period." (*Climacteric*, 2025, PMID 40937901)

That does not mean lifestyle is a magic switch. If you are waking drenched at 3 a.m., "drink water and do yoga" can feel insulting. The point is more practical: your nervous system is easier to trigger during the menopause transition, and small rises in core temperature, disrupted sleep, alcohol, caffeine, stress, and weight gain can all make the system more reactive. Mayo Clinic describes hot flashes as the hypothalamus responding to small changes in body temperature, which is why cooling, trigger control, and sleep routines can matter even when they sound basic (Mayo Clinic: Hot flashes).

"Evidence-based lifestyle interventions can mitigate menopausal symptoms and reduce risk of chronic disease across the lifespan." (*American Journal of Lifestyle Medicine*, 2026, DOI 10.1177/15598276261449751)

Why it matters: the same transition that drives hot flashes also reshapes metabolism and cardiovascular risk, so the foundation does double duty — symptom relief now, risk reduction later. A 2026 perimenopause review links hormonal fluctuation and irregular ovulation with vasomotor symptoms, sleep disturbance, mood and cognition changes, and increased visceral adiposity (*American Journal of Lifestyle Medicine*, 2026, DOI 10.1177/15598276261449751):

"Hormonal fluctuations and irregular ovulation can cause vasomotor symptoms (i.e., hot flashes, night sweats), sleep disturbances, mood and cognition issues, and increased risk of visceral adiposity." (*American Journal of Lifestyle Medicine*, 2026, DOI 10.1177/15598276261449751)

• Sleep hygiene + cooling for night sweats and menopausal insomnia. Think of this as lowering the "heat load" before your brain has a chance to overreact: keep the bedroom cool, use breathable layers, keep a fan or cool drink nearby, limit caffeine later in the day, reduce alcohol if it worsens sleep, and avoid heavy overheating close to bedtime. Night sweats can wake you repeatedly and create a sleep-deprivation loop, so the goal is not just comfort — it is protecting sleep continuity (Mayo Clinic Press: Relief from hot flashes).

• Movement — aerobic + resistance for weight, mood, bone, and cardiometabolic risk. Exercise may not stop a hot flash in the moment, but it helps the body handle the menopause transition better: regular activity supports weight maintenance, mood, sleep, cardiovascular health, and bone protection. During and after menopause, heart disease and osteoporosis risk rise, so movement is not just a symptom tactic; it is risk management. Aim for a mix of cardio you can repeat and strength work that tells muscle and bone, "stay." (MedlinePlus Magazine: Menopause)

• Nutrition & alcohol/caffeine triggers for hot flashes and weight. Food is not a cure for menopause, but your triggers may be real. Alcohol, spicy foods, caffeine, smoking, and higher body weight are commonly listed as factors that can worsen hot flashes or sleep for some people. If you are trying to ease hot flashes naturally, start with pattern-spotting rather than perfection: what happened in the few hours before the flare — wine, late coffee, a hot room, stress, a spicy meal, skipped food, poor sleep? Then test one change at a time. (MedlinePlus: Menopause)

• Stress / mind-body: CBT and mindfulness have trial support for menopausal symptoms and sleep, especially when insomnia, night sweats, anxiety, or rumination are feeding each other. CBT trials in perimenopausal and postmenopausal women with vasomotor symptoms have studied sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and behavioral homework; systematic reviews also support cognitive-behavioral and mindfulness-based approaches for menopause-related sleep and symptom burden (*Menopause* systematic review, PubMed).

Start here because it gives every other treatment a better surface to land on. Medication can be the right next step, and for moderate-to-severe hot flashes it often is. But your baseline — sleep, temperature, movement, food, alcohol, stress, smoking, and weight — changes how loud the symptoms feel in your body and how much reserve you have to deal with them.

Menopausal Hormone Therapy (MHT / HRT): The Most Effective Option for the Right Candidate

MHT is the single most effective treatment for moderate-to-severe hot flashes and night sweats. For the right person, that can mean fewer sudden heat surges, less sweat-soaked sleep, and a real chance to feel like your body is not hijacking the day. But "right person" matters. Candidacy is not defined by symptoms alone; it is defined by your age, how long it has been since menopause began, whether you have a uterus, your route and formulation options, and your personal history of clotting, cancer, cardiovascular disease, stroke, liver disease, and unexplained bleeding. The 2022 NAMS position statement says hormone therapy remains the most effective treatment for vasomotor symptoms, and that risk differs by type, duration, route, timing of initiation, and whether a progestogen is used (2022 NAMS Hormone Therapy Position Statement, PubMed).

"MHT is used in healthy symptomatic women under 60 or within 10 years of menopause without contraindications." (*Frontiers in Reproductive Health*, 2026, DOI 10.3389/frph.2025.1647721)

The "timing hypothesis" is the reason your start date matters. Starting MHT around the menopause transition is not the same risk conversation as starting it many years later. Your blood vessels, lipids, blood pressure, insulin sensitivity, and clotting risk are not static across midlife; the cardiovascular background changes as estrogen falls and aging continues.

"The risk of atherosclerotic heart disease accelerates during the menopause transition due to hormonal, metabolic, and vascular changes." (*Current Atherosclerosis Reports*, 2025, PMC12511246)

That is why the same symptom — "I'm having brutal night sweats" — can lead to different recommendations at 52 than at 68. In most healthy, symptomatic women who start before age 60 or within 10 years of menopause onset, the benefit-risk balance is generally considered favorable for bothersome vasomotor symptoms. After age 60, or when MHT is initiated more than 10 years after menopause onset, that balance becomes less favorable because the absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia rise (2022 NAMS Hormone Therapy Position Statement, PubMed).

And the older oral formulations are the reason many people still hear scary, oversimplified things about HRT. Some of that fear came from real trial signals, but it was not a clean match for every modern candidate or every route.

"Oral synthetic MHT, including conjugated equine estrogen (CEE) with medroxyprogesterone acetate (MPA), is associated with increased coronary heart disease and stroke risk, particularly in older, postmenopausal women." (*Current Atherosclerosis Reports*, 2025, PMC12511246)

Benefit and risk by age and start time: for many healthy women with disruptive symptoms, starting MHT before 60 or within 10 years of menopause is the window where benefits are most likely to outweigh risks. Later starts require a more cautious cardiovascular and clot-risk review. Route matters too: oral estrogen passes through the liver first and is more strongly linked with clot-related effects, while transdermal estrogen avoids first-pass liver metabolism and may have a more favorable clotting profile for some patients. That does not make a patch automatically "safe for everyone"; it makes route a clinical decision, not a beauty-blog preference (2022 NAMS Hormone Therapy Position Statement, PubMed).

Types and routes, at class level only: systemic MHT usually means estrogen, with a progestogen added if you have a uterus to protect the endometrium from unopposed estrogen stimulation. If you do not have a uterus, estrogen-only therapy may be considered. Estrogen can be given systemically by oral or non-oral routes, including transdermal forms; local vaginal estrogen is a different use case, mainly for genitourinary symptoms rather than whole-body hot flashes and night sweats (StatPearls: Estrogen (NCBI Bookshelf NBK493191)).

Who should not use systemic MHT is a clinician-decided safety screen, not a self-checklist. Common contraindications to oral or transdermal estrogen-based therapy include known, suspected, or past estrogen-sensitive breast cancer; known or suspected estrogen-related cancer; unexplained vaginal bleeding; active or past deep vein thrombosis or pulmonary embolism; thrombophilia or blood-clotting disorders; and active or past stroke. Estrogen therapy is also generally contraindicated with undiagnosed abnormal genital bleeding and active liver disease, and many clinical summaries include prior myocardial infarction in the "do not use without specialist review" category (StatPearls: Estrogen (NCBI Bookshelf NBK493191)).

Reassessment is part of the treatment, not an afterthought. If you and your clinician choose MHT, the plan should be individualized and revisited periodically: are symptoms controlled, are side effects appearing, has your health history changed, and is there still a documented reason to continue? Longer use is not automatically wrong, but it should be tied to persistent symptoms or another clear indication, with shared decision-making and regular benefit-risk review (2022 NAMS Hormone Therapy Position Statement, PubMed).

⚠️ Framing rule: this section names classes, indications, routes, contraindication categories, and the age/timing principle only. It does not give doses or tell you to start, stop, or switch hormones. MHT is always a decision to make with your clinician, especially if you have cardiovascular risk factors, a clotting history, cancer history, migraines with aura, liver disease, unexplained bleeding, or new symptoms after starting therapy.

Non-Hormonal Medication Options (For Those Who Can't or Prefer Not to Use Hormones)

When MHT isn't suitable or isn't what you want, several non-hormonal prescription options can still help turn down hot flashes and night sweats. They are not "natural fixes," and they are not instant rescue tools; they work through brain and nerve signaling, so the right choice depends on your medical history, other medications, sleep pattern, blood pressure, liver health, cancer history, and what side effects you most need to avoid.

• Certain antidepressant classes (SSRIs / SNRIs): these medicines may be used specifically for vasomotor symptoms, even when mood is not the main issue. The 2023 North American Menopause Society nonhormone therapy position statement lists SSRIs/SNRIs among recommended nonhormonal options for vasomotor symptoms; commonly studied agents in this class include paroxetine, citalopram, escitalopram, venlafaxine, and desvenlafaxine. In the U.S., paroxetine mesylate, sold as Brisdelle, is the SSRI with an FDA indication for moderate-to-severe vasomotor symptoms associated with menopause (2023 NAMS Nonhormone Therapy Position Statement, PubMed).

• Fezolinetant-class (neurokinin-3 / NK3 receptor antagonist): this is a newer non-hormonal class built for moderate-to-severe hot flashes rather than repurposed from another symptom area. Fezolinetant blocks NK3 receptor activity, which is involved in the brain's temperature-control pathways; in plain English, it targets part of the "thermostat" system that becomes more reactive as estrogen falls. The FDA approved fezolinetant for moderate-to-severe vasomotor symptoms due to menopause and later added a boxed warning for rare but serious liver injury, so clinicians check liver blood tests before treatment and during follow-up (FDA: Boxed warning for Veozah (fezolinetant) liver injury).

• Gabapentin: this is another non-hormonal prescription option for vasomotor symptoms and is sometimes considered when hot flashes are most disruptive at night or when sleep is part of the problem. It is not a hormone and it is not a supplement; it acts on nerve signaling, which is also why sleepiness, dizziness, balance issues, and other nervous-system side effects need to be part of the clinician conversation. The 2023 NAMS position statement lists gabapentin among recommended nonhormonal options for vasomotor symptoms; it does not give a green light to every "related" nerve-pain medicine as interchangeable (2023 NAMS Nonhormone Therapy Position Statement, PubMed).

• Non-hormonal mind-body care with trial support — CBT: CBT is not a drug, but it matters here because hot flashes and insomnia can reinforce each other: a night sweat wakes you, poor sleep makes your stress system more reactive, and the next night can feel even more fragile. A randomized pilot trial tested CBT designed for both menopausal insomnia and vasomotor symptoms:

"Cognitive behavioral therapy intervention for both insomnia and vasomotor symptoms (VMS) in perimenopausal and postmenopausal women with insomnia disorder." (*Menopause*, 2026, PMID 42084929)

⚠️ No doses here on purpose. These are clinician-level choices, not mix-and-match menopause hacks. Ask: "Which non-hormonal class fits my health history, my sleep, and my current medications — and what monitoring do I need?"

Genitourinary Symptoms (GSM): Vaginal Dryness, Discomfort, Urinary Symptoms

Vaginal and urinary symptoms of menopause are treated separately from systemic hot-flash therapy. GSM happens because lower estrogen changes the tissues of the vulva, vagina, and lower urinary tract: the lining can become thinner, drier, easier to irritate, and less elastic, which may show up as dryness, burning, pain with sex, urinary urgency, frequency, nighttime urination, or recurrent UTI-type symptoms (*Genitourinary syndrome of menopause* review, PMC4855283).

The first steps are usually non-hormonal: vaginal moisturizers for ongoing dryness and lubricants for friction during sex. They do different jobs. A moisturizer is used regularly to help dry tissue feel less raw over time; a lubricant is used right before sexual activity to reduce rubbing and pain in the moment. If you use condoms or diaphragms, avoid oil-based products because they can weaken latex (Mayo Clinic: Vaginal dryness).

If moisturizers and lubricants are not enough, low-dose vaginal estrogen is the targeted treatment option for GSM. It comes in local forms such as a cream, tablet, insert, or ring, and it is meant to act mainly on vaginal and urinary tissues rather than treat whole-body menopause symptoms like hot flashes. That local route matters: NHS patient guidance notes that vaginal estrogen does not carry the same risks as other types of HRT because the dose is low and only a small amount gets into the rest of the body. Still, it is prescription therapy, so decisions are individualized — especially if you have a history of breast cancer, hormone-sensitive cancer, unexplained bleeding, or complex urinary symptoms (NHS: About vaginal oestrogen).

The Long Game: Bone and Heart Health

Menopause treatment isn't only about quieting symptoms this week. It's also a chance to protect tissues that may not "complain" until years later: bone, blood vessels, blood pressure, lipids, and glucose metabolism. As estrogen falls, bone remodeling speeds up, and bone mineral density can drop fastest around the final menstrual period and early postmenopause. That's why the unglamorous base matters: progressive weight-bearing and resistance exercise, enough protein, adequate calcium and vitamin D, not smoking, limiting alcohol, and getting bone-risk screening when your clinician recommends it. For some people, menopausal hormone therapy can be part of bone protection because the 2022 NAMS position statement says hormone therapy helps prevent bone loss and fractures, with a more favorable benefit-risk profile for appropriate candidates who are younger than 60 or within 10 years of menopause onset. For others, fracture risk may call for osteoporosis-specific treatment instead, chosen with a clinician after risk assessment (2022 NAMS Hormone Therapy Position Statement, PubMed).

The heart side works the same way: menopause is not a single overnight switch, but the transition is a window when cardiovascular risk factors often start moving in the wrong direction — more central adiposity, a more atherogenic lipid pattern, glucose intolerance or insulin resistance, and higher blood-pressure risk. Lifestyle is the through-line because sleep, movement, muscle, nutrition, weight, smoking status, and blood pressure control keep shaping risk long after hot flashes fade. MHT is not a universal heart medicine; its cardiovascular effect depends on age, timing since menopause, baseline risk, formulation, route, and duration. That timing piece is why symptom treatment and long-term prevention belong in the same conversation: hot flashes, sleep, weight gain, bone density, cholesterol, blood pressure, diabetes risk, and whether MHT is reasonable for you are all connected in the same body (*Current Atherosclerosis Reports*, 2025, PMC12511246).

"Natural" and Supplement Claims — What the Evidence Really Says

"Natural" can sound safer than "medical," but your body does not read the label that way. A supplement still contains active chemicals. It can affect your liver, your bleeding risk, your thyroid function, your sleep, your gut, and the way prescription medicines behave in your bloodstream. That is why the honest answer is not "try these natural menopause treatments that really work." It is: some options may help some people a little, the evidence is uneven, and none of them should be framed as equivalent to menopausal hormone therapy or other evidence-based treatments for moderate-to-severe hot flashes and night sweats. Mayo Clinic notes that supplements used for hot flashes can have side effects and interact with medications, and that estrogen remains the most effective treatment for hot-flash discomfort when it is appropriate for the person taking it (Mayo Clinic: Hot flashes diagnosis & treatment).

Black cohosh is a good example of why this gets messy. It is heavily marketed for hot flashes and other menopause symptoms, and reviews do not all point in the same direction: some data suggest possible benefit for overall menopause symptoms, while older systematic reviews found conflicting results and major differences between products and study methods. Mayo Clinic describes the evidence as mixed and warns that black cohosh may rarely be harmful to the liver; NIH's LiverTox notes that products labeled as black cohosh have been linked to clinically apparent liver injury, sometimes severe, although the exact cause can be hard to prove because supplements may be mislabeled or adulterated (NCCIH: Black cohosh).

Phytoestrogens — plant compounds found in soy, red clover, flaxseed, legumes, whole grains, and some supplements — are another "maybe, but do not oversell it" category. They can act weakly like estrogen in the body, which is why they are promoted for hot flashes. But Mayo Clinic says research is unclear for menopause symptom relief, and NHS cautions that herbal and complementary products can vary in quality, purity, and ingredients. Food patterns that include soy or flax are different from concentrated pills; if you have a history of breast cancer or another estrogen-sensitive condition, this is a clinician conversation, not a checkout-cart decision (Mayo Clinic: Perimenopause diagnosis & treatment).

Ashwagandha is often sold for stress, sleep, "hormone balance," and menopause support, but that does not make it a proven menopause treatment. A few clinical trials are emerging, yet long-term safety is still not well established. NIH's Office of Dietary Supplements says ashwagandha appears to be tolerated for short-term use in studies, but long-term safety is unknown; it may affect thyroid function, may interact with medications, and has been linked in rare reports to liver injury. LiverTox also describes clinically apparent liver injury attributed to ashwagandha, while noting that products and formulations vary (NIH Office of Dietary Supplements: Ashwagandha).

⚠️ Supplement–medication safety. If you take blood thinners, thyroid medication, sedatives, liver-affecting medicines, cancer-related hormone treatments, or several prescriptions at once, do not add menopause supplements without asking your clinician or pharmacist. Mayo Clinic specifically warns that supplements can interact with medications; it also notes bleeding concerns with some products used for menopause symptoms, including dong quai and high-dose vitamin E. (Mayo Clinic: Hot flashes diagnosis & treatment)

The practical takeaway: treat supplements like biologically active products, not harmless wellness props. Bring the bottle or a photo of the label to your appointment. Ask three questions: "What symptom am I targeting?", "How will we know if it is working?", and "What risks matter for my health history and medications?" If the answer is vague, the product probably should not be the center of your menopause plan.

The Welltory Angle — Sleep, HRV & Recovery as the Context Others Miss

Menopause treatment is often measured in hot-flash counts: fewer flashes, shorter flashes, less disruption. That matters. But your body does not experience the transition as a neat symptom total. A night sweat can wake you up, leave you damp or chilled, and turn one bad episode into hours of broken sleep; over time, nighttime hot flashes can contribute to ongoing sleep loss. So the useful question is not only "Did I have fewer hot flashes?" It is also "Did I sleep through more of the night, wake up less often, and feel more recovered the next day?" Tracking sleep continuity, sleep quality, and next-day recovery gives you a way to see whether the plan you and your clinician chose — lifestyle changes, MHT, or a non-hormonal option — is helping the nights, not just the daytime heat (Mayo Clinic: Hot flashes).

HRV adds another layer, but it needs to be framed carefully. HRV is a noninvasive signal related to autonomic nervous system activity — the push-pull system that helps regulate heart rate, stress response, temperature shifts, and recovery. Some menopause studies have found lower vagal HRV patterns in women with more intense symptoms, especially vasomotor symptoms, while a recent systematic review found that pooled HRV differences between women with and without vasomotor symptoms were not statistically clear and called for larger, more standardized research. In plain English: HRV should not be sold as a menopause test. It is better used as a personal trend line. If your sleep fragments, stress climbs, alcohol or heat triggers symptoms, or a new routine helps you recover better, HRV may help you see that pattern sooner than a symptom diary alone (HRV and vasomotor symptoms systematic review, PMC6961890).

Recovery matters because menopause is also a cardiovascular transition, not only a temperature-control problem. The American Heart Association describes perimenopause as a period of vulnerability marked by changes in cardiometabolic and vascular health; during midlife, LDL cholesterol, metabolic syndrome risk, vascular remodeling, abdominal visceral fat, and loss of lean skeletal muscle can all become more relevant. That does not mean your wearable can diagnose cardiovascular risk. It means resting heart rate, HRV, sleep, activity, and recovery trends can give you low-effort feedback on how your body is responding over months — and a concrete reason to keep the lifestyle foundation going even when symptom relief is the main goal (American Heart Association: Menopause transition and CVD risk).

Welltory doesn't diagnose or treat menopause. It records the everyday signals — sleep, resting heart rate, HRV, activity, and recovery — so you can watch how your body responds to whatever plan you and your clinician choose. Positioning: track how your nights, HRV, and recovery respond over time, not as a diagnostic and not as a treatment claim.

How We Made It

Made with AI tools, then edited, fact-checked, and medically reviewed by the Welltory team.

We built this article from verified scientific excerpts and guideline-based framing (NAMS 2022 and 2023 position statements, ACOG, FDA, and NHS/NIH patient guidance). We deliberately kept it at the level of drug classes, indications, and the age/timing principle — it contains no drug doses, and every medication decision is described as individualized and clinician-led.

This article is educational and does not provide diagnosis or treatment instructions. For personal medical decisions, including hormone therapy or any prescription choice, work with a licensed clinician.

Evidence Base

• Lifestyle medicine in menopause — review (Climacteric, 2025) — PMID 40937901.

• Perimenopause & lifestyle medicine — review (American Journal of Lifestyle Medicine, 2026) — DOI 10.1177/15598276261449751 — vasomotor symptoms, sleep, mood/cognition, visceral adiposity.

• MHT candidacy window (Frontiers in Reproductive Health, 2026) — DOI 10.3389/frph.2025.1647721 — MHT in healthy symptomatic women under 60 or within 10 years of menopause.

• Cardiovascular risk across the menopause transition (Current Atherosclerosis Reports, 2025) — PMC12511246 — atherosclerotic risk acceleration; oral CEE+MPA CHD/stroke signal.

• CBT for menopausal insomnia + VMS (randomized pilot) (Menopause, 2026) — PMID 42084929.

• 2022 NAMS Hormone Therapy Position Statement — PubMed 35797481 — HT most effective for VMS; benefit-risk by age/timing; route (transdermal vs oral); bone protection.

• 2023 NAMS Nonhormone Therapy Position Statement — PubMed 37252752 — SSRIs/SNRIs, gabapentin, oxybutynin, fezolinetant, CBT, clinical hypnosis (no doses cited here).

• FDA — fezolinetant (Veozah) boxed warning for rare serious liver injury — FDA Drug Safety Communication.

• Estrogen — class, routes, contraindications (StatPearls) — NCBI Bookshelf NBK493191.

• Genitourinary syndrome of menopause — review — PMC4855283.

• NHS — vaginal oestrogen (local, low-dose; risk profile vs systemic HRT) — NHS: About vaginal oestrogen.

• Supplements & interactions — Mayo Clinic: Hot flashes; NCCIH: Black cohosh; NIH ODS: Ashwagandha.

• HRV & vasomotor symptoms — systematic review — PMC6961890.

• Menopause transition & cardiovascular disease risk — American Heart Association.

• Patient-education framing — Cleveland Clinic: Menopause treatment; Mayo Clinic: Menopause; MedlinePlus: Menopause; National Institute on Aging: Sex and menopause.

Discounts for blog readers: up to 36% off

See what affects your energy, stress, sleep, and daily state with Welltory

Explore your data